Cannabis Consumption Index Report

The Consumption Index Report: When Potency Fails, the Consumer Notices

The cannabis industry has spent years focused on scaling products, expanding categories, and competing on branding. But at its core, this is still a performance-based industry. If the product doesn’t perform, nothing else matters.

A recent Informational Notification issued by the Colorado Department of Revenue (DOR) and the Colorado Department of Public Health and Environment (CDPHE) highlighted a critical issue involving Keef-branded THC beverages produced by Denver Packaging Company (doing business as Keef). These products were found to contain lower THC levels than what was stated on the label, exceeding the allowable 15% variance threshold set by regulators.

On paper, this is a compliance issue. In reality, this is a consumer trust problem—and a category risk.

How a Compliance Issue Becomes a Market Issue

The real problem isn’t THC—it’s expectation. Cannabis consumers don’t just buy products; they buy outcomes. When a product is labeled at 100mg, the consumer expects a certain level of intensity, a predictable onset, and a repeatable experience. When that expectation isn’t met, the consumer doesn’t say the batch tested low—they say the product is weak. That difference is everything.

From a Consumption Index perspective, potency inconsistency creates three immediate impacts.

First, dose reliability breaks. Consumers begin adjusting their intake to compensate. They drink more, wait longer, or abandon the product altogether. What should be a controlled experience becomes unpredictable.

Second, velocity declines quietly. At first, nothing appears wrong. Products continue to sell because consumers don’t immediately recognize the issue. But within weeks, repeat purchases slow, basket inclusion drops, and products begin to stagnate on shelves. Velocity doesn’t crash—it erodes.

Third, the category takes the hit. When beverages underperform, consumers generalize. They begin to believe THC drinks are inconsistent or ineffective. This shifts demand back toward other formats like flower, vapes, or traditional edibles.

This situation is not just a labeling issue—it’s a manufacturing issue. It points to deeper operational challenges such as inconsistent infusion processes, unstable emulsions, lack of batch-level validation, and potential THC degradation over time. The industry is still catching up to the reality that precision matters more than scale.

Cannabis is now entering a performance-driven phase. Consumers are no longer buying what’s printed on the label—they’re buying what they feel. This shift will separate the market.

The brands that win will not be the loudest. They will be the most consistent—delivering predictable dosing, reliable onset, and repeatable results.

Because in the end, consumers don’t remember THC percentages. They remember whether it worked.